Tumor size and effectiveness of electrochemotherapy

Radiology and Oncology

Volumn 47, Issue 1, 2013, Pages 32-41

  Mali, Barbara ^a   Miklavcic, Damijan ^a   Campana, Luca G ^b   Cemazar, Maja ^c   Sersa, Gregor ^a   Snoj, Marko ^c   Jarm, Tomaz ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

Cutaneous tumors; Effectiveness; Electrochemotherapy; Meta analysis; Tumor size

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; DRUG EFFICACY; ELECTROCHEMOTHERAPY; HUMAN; META ANALYSIS; PROBABILITY; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TUMOR VOLUME;

EID: 84877997986     PISSN: 13182099     EISSN: 15813207     Source Type: Journal    
DOI: 10.2478/raon-2013-0002     Document Type: Article

References (39)

1. Marty M, Sersa G, Garbay JR, Gehl J, Collins CG, Snoj M, et al. Electrochemotherapy-An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. Eur J Cancer Suppl 2006;4: 3-13.
2. Sersa G, Miklavcic D, Cemazar M, Rudolf Z, Pucihar G, Snoj M. Electrochemotherapy in treatment of tumours. Eur J Surg Oncol 2008;34: 232-240.
3. Snoj M, Rudolf Z, Cemazar M, Jancar B, Sersa G. Successful sphincter-saving treatment of anorectal malignant melanoma with electrochemotherapy, local excision and adjuvant brachytherapy. Anticancer Drugs 2005;16: 345-348.
4. Snoj M, Cemazar M, Srnovrsnik T, Paulin-Kosir SM, Sersa G. Limb sparing treatment of bleeding melanoma recurrence by electrochemotherapy. Tumori 2009;95: 398-402.
5. Colombo GL, Di Matteo S, Mir LM. Cost-effectiveness analysis of electrochemotherapy with the CliniporatorTM vs other methods for the control and treatment of cutaneous and subcutaneous tumors. Ther Clin Risk Manag 2008;4: 541-548.
6. Moller MG, Salwa S, Soden DM, O'Sullivan GC. Electrochemotherapy as an adjunct or alternative to other treatments for unresectable or in-Transit melanoma. Expert Rev Anticancer Ther 2009;9: 1611-1630.
7. Testori A, Faries MB, Thompson JF, Pennacchioli E, Deroose JP, van Geel AN, et al. Local and intralesional therapy of in-Transit melanoma metastases. J Surg Oncol 2011;104: 391-396.
8. Mir LM, Gehl J, Sersa G, Collins CG, Garbay JR, Billard V, et al. Standard operating procedures of the electrochemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or noninvasive electrodes. Eur J Cancer Suppl 2006;4: 14-25.
9. Campana LG, Mocellin S, Basso M, Puccetti O, De Salvo GL, Chiarion-Sileni V, et al. Bleomycin-based electrochemotherapy: clinical outcome from a single institution's experience with 52 patients. Ann Surg Oncol 2009;16: 191-199.
10. Curatolo P, Quaglino P, Marenco F, Mancini M, Nardo T, Mortera C, et al. Electrochemotherapy in the treatment of Kaposi sarcoma cutaneous lesions: a two-center prospective phase II trial. Ann Surg Oncol 2012;19: 192-198.
11. Quaglino P, Mortera C, Osella-Abate S, Barberis M, Illengo M, Rissone M, et al. Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases. Ann Surg Oncol 2008;15: 2215-2222.
12. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-Analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339: b2700.
13. Wieseler B, McGauran N. Reporting a systematic review. Chest 2010;137: 1240-1246.
14. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. UK: Wiley-Blackwell;2008.
15. World Health Organization. WHO handbook for reporting results of cancer treatment. Switzerland: World Health Organization;1979.
16. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92: 205-216.
17. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to metaanalysis. UK: Wiley;2009.
18. Byrne CM, Thompson JF, Johnston H, Hersey P, Quinn MJ, Hughes TM, et al. Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy). Melanoma Res 2005;15: 45-51.
19. Landstrom FJ, Nilsson COS, Crafoord S, Reizenstein JA, Adamsson GBM, Lofgren LA. Electroporation therapy of skin cancer in the head and neck area. Dermatol Surg 2010;36: 1245-1250.
20. Larkin JO, Collins CG, Aarons S, Tangney M, Whelan M, O'Reily S, et al. Electrochemotherapy-Aspects of preclinical development and early clinical experience. Ann Surg 2007;245: 469-479.
21. Matthiessen LW, Chalmers RL, Sainsbury DCG, Veeramani S, Kessell G, Humphreys AC, et al. Management of cutaneous metastases using electrochemotherapy. Acta Oncol 2011;50: 621-629.
22. Rols MP, Bachaud JM, Giraud P, Chevreau C, Roche H, Teissie J. Electrochemotherapy of cutaneous metastases in malignant melanoma. Melanoma Res 2000;10: 468-474.
23. Domenge C, Orlowski S, Luboinski B, DeBaere T, Schwaab G, Belehradek J, et al. Antitumor electrochemotherapy-New advances in the clinical protocol. Cancer 1996;77: 956-963.
24. Miklavcic D, Beravs K, Semrov D, Cemazar M, Demsar F, Sersa G. The importance of electric field distribution for effective in vivo electroporation of tissues. Biophys J 1998;74: 2152-2158.
25. Miklavcic D, Corovic S, Pucihar G, Pavselj N. Importance of tumour coverage by sufficiently high local electric field for effective electrochemotherapy. Eur J Cancer Suppl 2006;4: 45-51.
26. Miklavcic D, Towhidi L. Numerical study of the electroporation pulse shape effect on molecular uptake of biological cells. Radiol Oncol 2010;44: 34-41.
27. Cemazar M, Milacic R, Miklavcic D, Dolzan V, Sersa G. Intratumoral cisplatin administration in electrochemotherapy: antitumor effectiveness, sequence dependence and platinum content. Anticancer Drugs 1998;9: 525-530.
28. Front D, Israel O, Iosilevsky G, Even-Sapir E, Ben-Haim S, Frenkel A, et al. Administered dose and tumor dose of bleomycin labeled with cobalt-57 in mice and men. J Nucl Med 1990;31: 1784-1790.
29. Mir LM, Tounekti O, Orlowski S. Bleomycin: Revival of an old drug. Gen Pharmac 1996;27: 745-748.
30. Hall SW, Strong JE, Broughton A, Frazier ML, Benjamin RS. Bleomycin clinical pharmacology by radioimmunoassay. Cancer Chemother Pharmacol 1982;9: 22-25.
31. Alberts DS, Chen HS, Liu R, Himmelstein KJ, Mayersohn M, Perrier D, et al. Bleomycin pharmacokinetics in man. I. Intravenous administration. Cancer Chemother Pharmacol 1978;1: 177-181.
32. Sersa G, Jarm T, Kotnik T, Coer A, Podkrajsek M, Sentjurc M, et al. Vascular disrupting action of electroporation and electrochemotherapy with bleomycin in murine sarcoma. Br J Cancer 2008;98: 388-398.
33. Sersa G, Krzic M, Sentjurc M, Ivanusa T, Beravs K, Kotnik V, et al. Reduced blood flow and oxygenation in SA-1 tumours after electrochemotherapy with cisplatin. Br J Cancer 2002;87: 1047-1054.
34. Sersa G, Cemazar M, Miklavcic D. Tumor blood flow modifying effects of electrochemotherapy: a potential vascular targeted mechanism. Radiol Oncol 2003;37: 43-48.
35. Jarm T, Cemazar M, Miklavcic D, Sersa G. Antivascular effects of electrochemotherapy: implications in treatment of bleeding metastases. Expert Rev Anticancer Ther 2010;10: 729-746.
36. Miklavcic D, Snoj M, Zupanic A, Kos B, Cemazar M, Kropivnik M, et al. Towards treatment planning and treatment of deep-seated solid tumors by electrochemotherapy. BioMed Eng OnLine 2010;9: 10.
37. Edhemovic I, Gadzijev EM, Brecelj E, MIklavcic M, Kos B, Zupanic A, et al. Electrochemotherapy: a new technological approach in treatment of metastases in the liver. Technol Cancer Res Treat 2011;10: 475-485.
38. Pavliha D, Kos B, Zupanic A, Marcan M, Sersa G, Miklavcic D. Patient-specific treatment planning of electrochemotherapy: Procedure design and possible pitfalls. Bioelectrochemistry 2012;87: 265-273.
39. Adeyanju OO, Al-Angari HM, Sahakian AV. The optimization of needle electrode number and placement for irreversible electroporation of hepatocellular carcinoma. Radiol Oncol 2012;46: 126-135.